Android app Apple app link

Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form

By Yahoo! Finance   |   2 weeks ago
Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form

Merck's Keytruda cancer drug shows promise in injection form, potentially expanding treatment options. Analysts predict mixed impact on Merck's revenue due to patent expiration and pricing differences between injection and IV forms. FDA decision on approval expected by September 23.

Read More

Did you find this insightful?

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.